Hepatic artery thrombosis (HAT) is the most common vascular complication after liver transplantation; it has been reported to occur in 2% to 5% of liver transplant recipients. Most reports of HAT in the literature describe single-center series with small numbers of patients and lack the power to definitively identify nontechnical risk factors. We used the United Network for Organ Sharing databa...

This paper analyzes the cost of breaking ECC under the following assumptions: (1) ECC is using a standardized elliptic curve that was actually chosen by an attacker; (2) the attacker is aware of a vulnerability in some curves that are not publicly known to be vulnerable. This cost includes the cost of exploiting the vulnerability, but also the initial cost of computing a curve suitable for sabo...

According to the World Health Organization, human African trypanosomiasis (HAT) (sleeping sickness) caused the loss of approximately 1.5 million disability-adjusted life years (DALYs) in 2002. We describe the effect of HAT during 2000-2002 in Buma, a rural community near Kinshasa in the Democratic Republic of Congo. We used retrospective questionnaire surveys to estimate HAT-related household c...

Reactions of Fe(II) salts with the ligand 1,4,5,8,9,12-hexaazatriphenylene (HAT) led to the isolation and characterization of four new compounds: [Fe3(HAT)(H2O)12](SO4)3.3.3H2O (1), [Fe2(HAT)(SO4)(H2O)5](SO4).2H2O.CH3OH (2), [Fe2(HAT)(SO4)(H2O)5](SO4).3H2O (3), and [Fe3Cl5(HAT)(CH3OH)4(H2O)]Cl (4). Compound 1 crystallizes as a trinuclear cluster in which HAT acts as a tris-chelating ligand. Com...

BACKGROUND Definitive treatment for late hepatic artery thrombosis (L-HAT) is retransplantation (re-LT); however, the L-HAT-associated disease burden is poorly represented in allocation models. METHODS Graft access and transplant outcome of the re-LT experience between 2005 and 2016 was reviewed with specific focus on the L-HAT cohort in this single-center retrospective study. RESULTS Ninet...